Contrasting Oncology Pharma (OTCMKTS:ONPH) and VTEX (NYSE:VTEX)

Oncology Pharma (OTCMKTS:ONPH) and VTEX (NYSE:VTEX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Oncology Pharma and VTEX, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Pharma	0	0	0	0	N/A
VTEX	0	0	5	0	3.00

VTEX has a consensus target price of $10.40, indicating a potential upside of 56.39%.

Earnings and Valuation

This table compares Oncology Pharma and VTEX”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Pharma	N/A	N/A	N/A	N/A	N/A
VTEX	$201.52 million	6.07	-$13.69 million	$0.03	221.74

Oncology Pharma has higher earnings, but lower revenue than VTEX.

Risk and Volatility

Oncology Pharma has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, VTEX has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Oncology Pharma and VTEX’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Pharma	N/A	N/A	N/A
VTEX	1.51%	1.36%	0.97%

Insider and Institutional Ownership

63.7% of VTEX shares are held by institutional investors. 18.0% of Oncology Pharma shares are held by insiders. Comparatively, 40.9% of VTEX shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

VTEX beats Oncology Pharma on 8 of the 8 factors compared between the two stocks.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About VTEX

VTEX provides software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce strategy, including building online stores, integrating, and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It has operations in Brazil, Argentina, Chile, Colombia, France, Italy, Mexico, Peru, Portugal, Romania, Singapore, Spain, the United Kingdom, and the United States. VTEX was founded in 2000 and is headquartered in London, the United Kingdom.